Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14200237 | 0.87 | ACLY (0.50) | EPHX2KIF11NR3C2ACLYTRPV1 | |
| SCHEMBL1733478 | 0.82 | BRD4 (0.49) | KIF11BRD4ACLYKEAP1 | |
| SCHEMBL12115602 | 0.82 | GABRA1 (0.52) | EPHX2NR3C2ACLYTRPV1NR1H4 | |
| SCHEMBL16658370 | 0.82 | KIF11 (0.53) | EPHX2KIF11BRD4NR3C2ACLY | |
| SCHEMBL19047495 | 0.80 | EPHX2 (0.43) | EPHX2KIF11NR3C2ACLYTRPV1 | |
| SCHEMBL4953823 | 0.79 | EPHX2 (0.42) | EPHX2KIF11NR3C2ACLYTRPV1 | |
| SCHEMBL26682976 | 0.77 | RAPGEF4 (0.41) | — | |
| SCHEMBL19047494 | 0.76 | EPHX2 (0.40) | EPHX2KIF11NR3C2ACLYTRPV1 | |
| SCHEMBL13802151 | 0.76 | BRD4 (0.44) | KIF11BRD4KEAP1 | |
| SCHEMBL25005829 | 0.75 | MEN1 (0.35) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | EPHX2 2808/4885KIF11 2647/4885BRD4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.